PMID- 28962111
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210910
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 14
IP  - 3
DP  - 2017 Sep
TI  - MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma 
      via inhibiting EZH2 and PI3K/AKT signaling.
PG  - 1967-1974
LID - 10.3892/etm.2017.4733 [doi]
AB  - MicroRNA (miR)-138 generally has a suppressive role in various human cancer 
      types; however, its role and the underlying mechanisms in laryngeal squamous cell 
      carcinoma (LSCC) have remained to be elucidated. The present study assessed the 
      clinical significance and regulatory mechanisms of miR-138 in LSCC progression. 
      Reverse-transcription quantitative polymerase chain reaction analysis indicated 
      that miR-138 was significantly downregulated in LSCC tissues and cell lines. In 
      addition, the decreased expression of miR-138 was significantly associated with 
      poor differentiation, lymph node metastasis and advanced clinical stage of LSCC. 
      Restoration of miR-138 expression caused a significant decrease in the 
      proliferation of Hep-2 LSCC cells, while knockdown of miR-138 significantly 
      promoted Hep-2 cell proliferation. A luciferase reporter assay further identified 
      enhancer of zeste homologue 2 (EZH2) as a direct target gene of miR-138, and the 
      protein expression of EZH2 was negatively regulated by miR-138 in Hep-2 cells. 
      Furthermore, overexpression of EZH2 eliminated the suppressive effects of miR-138 
      on Hep-2 cell proliferation via activation of phosphoinositide-3 kinase 
      (PI3K)/AKT signaling. In addition, EZH2 was found to be significantly upregulated 
      in LSCC tissues and to be inversely correlated to the miR-138 levels. The results 
      of the present study demonstrated that miR-138 inhibits the proliferation of LSCC 
      cells, at least partly via targeting EZH2 and inhibiting PI3 K/AKT signaling. The 
      present study highlighted the clinical significance of the miR-138/EZH2 axis in 
      LSCC.
FAU - Si, Fengzhi
AU  - Si F
AD  - Department of Otorhinolaryngology, The Second Hospital of Xinjiang Medical 
      University, Urumqi, Xinjiang 830063, P.R. China.
FAU - Sun, Jie
AU  - Sun J
AD  - Department of Otorhinolaryngology, The Second Hospital of Xinjiang Medical 
      University, Urumqi, Xinjiang 830063, P.R. China.
FAU - Wang, Chunli
AU  - Wang C
AD  - Department of Otorhinolaryngology, The Second Hospital of Xinjiang Medical 
      University, Urumqi, Xinjiang 830063, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20170709
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
RIN - Exp Ther Med. 2021 Oct;22(4):1090. PMID: 34504544
PMC - PMC5609183
OTO - NOTNLM
OT  - enhancer of zeste homologue 2
OT  - laryngeal squamous cell carcinoma
OT  - microRNA
OT  - proliferation
EDAT- 2017/10/01 06:00
MHDA- 2017/10/01 06:01
PMCR- 2017/07/09
CRDT- 2017/10/01 06:00
PHST- 2016/06/16 00:00 [received]
PHST- 2017/04/11 00:00 [accepted]
PHST- 2017/10/01 06:00 [entrez]
PHST- 2017/10/01 06:00 [pubmed]
PHST- 2017/10/01 06:01 [medline]
PHST- 2017/07/09 00:00 [pmc-release]
AID - ETM-0-0-4733 [pii]
AID - 10.3892/etm.2017.4733 [doi]
PST - ppublish
SO  - Exp Ther Med. 2017 Sep;14(3):1967-1974. doi: 10.3892/etm.2017.4733. Epub 2017 Jul 
      9.